Trial results

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke

NCT05630586 on ClinicalTrials.gov · last registry update 2023-04-25

An unusually large phase 2: 380 participants, more than double the 114 typical for the stage. Its estimated completion date, September 2025, has passed with no update to the record. Primary outcome, as filed: Modified Ranking Scale. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P2

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Aarhus University Hospital

Sponsor type

Other

Enrollment

380

Started

2023-04-12

Primary completion

2025-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Modified Ranking Scale

Conditions studied

Acute Ischemic Stroke

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.